国金证券给予羚锐制药买入评级：银谷整合推进中，业绩持续稳健增长

Group 1 - The core viewpoint of the report is that Guojin Securities has given a "buy" rating to Lingrui Pharmaceutical (600285.SH, latest price: 23.25 yuan) [2] - The acquisition of Yingu Pharmaceutical is expected to empower the long-term development of Lingrui Pharmaceutical [2] - The new indication for the phenyl ring quaternary ammonium nasal spray is anticipated to enhance sales potential [2]